Skip to main content
Erschienen in: Journal of Experimental & Clinical Cancer Research 1/2021

Open Access 01.12.2021 | Retraction Note

Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors

verfasst von: Jie Yuan, Fan Zhang, Dennis Hallahan, Zhen Zhang, Liming He, Ling-Gang Wu, Meng You, Qin Yang

Erschienen in: Journal of Experimental & Clinical Cancer Research | Ausgabe 1/2021

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN
Hinweise
The original article can be found online at https://​doi.​org/​10.​1186/​s13046-018-0857-5.
Retraction Note: J Exp Clin Cancer Res 37, 181 (2018)
https://doi.org/10.1186/s13046-018-0857-5
The Editor-in-Chief has retracted this article. An investigation by the Office of the Vice Chancellor for Research at Washington University in St. Louis concluded that:
  • Figure panels 2a-f, labeled as the brain cancer cell line GBM U118, appeared to be falsified and/or fabricated, and were also used in multiple NIH grant applications as the brain cancer cell line GM139 or as the IMR90 cell line.
  • Figure 3 appeared to be produced by cutting out and reusing three lanes from a heatmap that was previously used in a 2014 NIH grant application. The heatmap lanes in the grant application were labelled as iOPCs, WT (dermal fibroblasts) and OPC (Ctrl), while the lanes in Figure 3 in this publication were labeled as iN, GBM cells and Ctrl neuron.
  • Figure 4c, labeled as iN cells in the 2018 this publication, appeared to be falsified and/or fabricated, and was also published in [1] labeled as iRLs from the breast cancer cell line MDA-MB-468.
  • Figure panel 4d, labeled as GBM U18 cells, appeared to be produced by reusing, manipulating, and relabeling photographs from Figure 1c labeled as IMR90 cells in [2].
  • An additional concern identified as part of the investigation is extensive overlap between this publication and [1].
In addition, the authors have been unable to provide any records of ethics approval for the animal study to the Editor. Limeng He and Zhen Zhang have stated that they were not aware of their inclusion in the author list of this study.
Dennis Hallahan, Zhen Zhang, Liming He and Ling-gang Wu agree to this retraction. Jie Yuan, Fan Zhang, Meng You and Qin Yang have not responded to any correspondence from the editor or publisher about this retraction.
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://​creativecommons.​org/​licenses/​by/​4.​0/​. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
download
DOWNLOAD
print
DRUCKEN
Metadaten
Titel
Retraction Note: Reprogramming glioblastoma multiforme cells into neurons by protein kinase inhibitors
verfasst von
Jie Yuan
Fan Zhang
Dennis Hallahan
Zhen Zhang
Liming He
Ling-Gang Wu
Meng You
Qin Yang
Publikationsdatum
01.12.2021
Verlag
BioMed Central
Erschienen in
Journal of Experimental & Clinical Cancer Research / Ausgabe 1/2021
Elektronische ISSN: 1756-9966
DOI
https://doi.org/10.1186/s13046-021-02172-6

Weitere Artikel der Ausgabe 1/2021

Journal of Experimental & Clinical Cancer Research 1/2021 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.